Kadakkal Radhakrishnan
Research Subjects
Kadakkal Radhakrishnan has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Senthilkumar Sankararaman
Division of Pediatric Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, UH Rainbow Babies and Children’s Hospital, Cleveland, OH 44106, USA
4 shared publications - Charles B. Chen
Department of Child Health, University of Missouri School of Medicine, Columbia, USA
3 shared publications - Kristina Pytlak
Cleveland Clinic Children’s Hospital
2 shared publications - Mohammad Nasser Kabbany
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
2 shared publications - Adriano Roberto Tonelli
Department of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, OH
1 shared publication - Ahmet Ozen
Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 6 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6901
Overview of Non-Cirrhotic Portal Hypertension in Pediatric Patients
Non-cirrhotic portal hypertension (NCPHT) is defined as portal hypertension (PHT) occurring in the absence of cirrhosis. Major etiological causes of NCPHT include immunological disorders, chronic infections, exposure to medications or toxins, prothrombotic conditions, and several genetic syndromes, highlighting that NCPHT is not a single disease but a shared phenotype arising from diverse underlying pathways. NCPHT is frequently misdiagnosed, largely due to inconsistent nomenclature and limited scientific literature. The broader term non-cirrhotic portal fibrosis (NCPF) or porto-sinusoidal vascular disease (PSVD) includes patients in a preclinical stage who demonstrate histological features similar to NCPHT but lack clinical evidence of PHT. Early detection is linked to a favorable prognosis and improved clinical outcomes. Management strategies in pediatrics continue to rely on extrapolations from adult practice, with sparse evidence to guide pediatric care. Liver biopsy remains the cornerstone of diagnosis, demonstrating nodular regenerative hyperplasia, obliterative portal venopathy, or incomplete septal fibrosis. Management focuses on prophylactic and symptomatic care, with endoscopic therapy for controlling variceal bleeding. Porto-systemic shunts and, ultimately, liver transplantation therapies may be needed for advanced stages. A pressing need exists for standardized diagnostic criteria and multicenter studies to define natural history, refine risk stratification, and evaluate therapeutic approaches in the pediatric population. This review provides an overview of the pediatric causes of NCPHT, outlines the current understanding of pathophysiology, and discusses the clinical presentations and management strategies, while highlighting existing research gaps.
- 6 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6901
Open AccessOverview of Non-Cirrhotic Portal Hypertension in Pediatric Patients
Non-cirrhotic portal hypertension (NCPHT) is defined as portal hypertension (PHT) occurring in the absence of cirrhosis. Major etiological causes of NCPHT include immunological disorders, chronic infections, exposure to medications or toxins, prothrombotic conditions, and several genetic syndromes, highlighting that NCPHT is not a single disease but a shared phenotype arising from diverse underlying pathways. NCPHT is frequently misdiagnosed, largely due to inconsistent nomenclature and limited scientific literature. The broader term non-cirrhotic portal fibrosis (NCPF) or porto-sinusoidal vascular disease (PSVD) includes patients in a preclinical stage who demonstrate histological features similar to NCPHT but lack clinical evidence of PHT. Early detection is linked to a favorable prognosis and improved clinical outcomes. Management strategies in pediatrics continue to rely on extrapolations from adult practice, with sparse evidence to guide pediatric care. Liver biopsy remains the cornerstone of diagnosis, demonstrating nodular regenerative hyperplasia, obliterative portal venopathy, or incomplete septal fibrosis. Management focuses on prophylactic and symptomatic care, with endoscopic therapy for controlling variceal bleeding. Porto-systemic shunts and, ultimately, liver transplantation therapies may be needed for advanced stages. A pressing need exists for standardized diagnostic criteria and multicenter studies to define natural history, refine risk stratification, and evaluate therapeutic approaches in the pediatric population. This review provides an overview of the pediatric causes of NCPHT, outlines the current understanding of pathophysiology, and discusses the clinical presentations and management strategies, while highlighting existing research gaps.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (9)
Memantine-Induced Cholestasis and Acute Hepatitis in an 8-Week-Old Term Infant
Cholestasis and hepatitis in infants occur for various reasons and require further evaluation. We present an 8-week-old term male infant with cholestasis secondary to breast milk transference of memantine. To the best of our knowledge, this is the first case associated with cholestasis and acute hepatitis with memantine transference through breast-feeding.
- 1 September 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (9)
Open AccessMemantine-Induced Cholestasis and Acute Hepatitis in an 8-Week-Old Term Infant
Cholestasis and hepatitis in infants occur for various reasons and require further evaluation. We present an 8-week-old term male infant with cholestasis secondary to breast milk transference of memantine. To the best of our knowledge, this is the first case associated with cholestasis and acute hepatitis with memantine transference through breast-feeding.
- Open Access
- 31 August 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (5) , e70241
Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa
Glycogen storage disease type Ia (GSDIa) is a rare, life‐threatening inherited carbohydrate metabolism disorder caused by biallelic pathogenic G6PC gene variants resulting in deficiency of glucose‐6‐phosphatase. DTX401 is an investigational AAV8 vector containing the human G6PC gene. DTX401‐CL301 is a pivotal, phase 3, double‐blind, randomized, placebo‐controlled trial of DTX401 in patients ≥ 8 years with GSDIa. The primary endpoint was percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 versus placebo group. Participants were randomly assigned (1:1) to blinded DTX401 or placebo. After the 48‐week Primary Efficacy Analysis Period (PEAP), participants crossed over in a blinded manner for an additional 48‐week blinded Crossover Period. Following randomization: 21 participants received DTX401; 25 received placebo. At Week 48, DTX401 treatment resulted in a statistically significant least squares (LS) mean (SE) daily cornstarch intake reduction of 41% (4.6) versus 10% (4.1) for Placebo ( p < 0.0001). Clinical meaningfulness was evidenced by a mean desired percent reduction in daily cornstarch intake among those reporting in Baseline interviews ( n = 33) of 45% (median = 41%). Greater and faster reductions in cornstarch were observed at Week 96 for the Crossover DTX401 group compared with the DTX401 group in the PEAP. The DTX401 safety profile was acceptable, and expected hepatic reactions consisting of transaminase elevations were managed with prophylactic corticosteroids. Treatment with DTX401 resulted in both a statistically significant and clinically meaningful reduction in cornstarch intake in the 48‐week PEAP versus placebo, with greater cornstarch reductions in both groups at Week 96.
- 31 August 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (5) , e70241
Open AccessPhase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa
Glycogen storage disease type Ia (GSDIa) is a rare, life‐threatening inherited carbohydrate metabolism disorder caused by biallelic pathogenic G6PC gene variants resulting in deficiency of glucose‐6‐phosphatase. DTX401 is an investigational AAV8 vector containing the human G6PC gene. DTX401‐CL301 is a pivotal, phase 3, double‐blind, randomized, placebo‐controlled trial of DTX401 in patients ≥ 8 years with GSDIa. The primary endpoint was percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 versus placebo group. Participants were randomly assigned (1:1) to blinded DTX401 or placebo. After the 48‐week Primary Efficacy Analysis Period (PEAP), participants crossed over in a blinded manner for an additional 48‐week blinded Crossover Period. Following randomization: 21 participants received DTX401; 25 received placebo. At Week 48, DTX401 treatment resulted in a statistically significant least squares (LS) mean (SE) daily cornstarch intake reduction of 41% (4.6) versus 10% (4.1) for Placebo ( p < 0.0001). Clinical meaningfulness was evidenced by a mean desired percent reduction in daily cornstarch intake among those reporting in Baseline interviews ( n = 33) of 45% (median = 41%). Greater and faster reductions in cornstarch were observed at Week 96 for the Crossover DTX401 group compared with the DTX401 group in the PEAP. The DTX401 safety profile was acceptable, and expected hepatic reactions consisting of transaminase elevations were managed with prophylactic corticosteroids. Treatment with DTX401 resulted in both a statistically significant and clinically meaningful reduction in cornstarch intake in the 48‐week PEAP versus placebo, with greater cornstarch reductions in both groups at Week 96.
- 24 November 2025
- Published by Springer Nature
- p. 97-110
Proteins and Amino Acids
- 24 November 2025
- Published by Springer Nature
- p. 311-316
Vitamin C
- 24 November 2025
- Published by Springer Nature
- p. 265-270
Vitamin B2: Riboflavin
- 24 November 2025
- Published by Springer Nature
- p. 85-95
Fat
- 24 November 2025
- Published by Springer Nature
- p. 249-264
Vitamin B1: Thiamine